Hypertrophic cardiomyopathy is a genetic disorder of the myocardium, characterized by marked myocardial hypertrophy that may lead to the development of symptoms such as dyspnea, angina pectoris, or stress-induced syncopes, with an increased risk of sudden cardiac death, due to obstruction of the left ventricular outflow tract (hypertrophic obstructive cardiomyopathy). Septal reduction treatment is needed in these patients, in order to relieve of the symptoms. In addition, mitral valve apparatus should be assessed in these patients, in order to recognize a dynamic movement of the MV during systole anteriorly toward the LVOT. In this chapter, we will describe the current surgical management of HOCM.
Part of the book: Cardiac Surgery Procedures
Heart failure is a growing disease that affects millions of people around the world. Heart transplantation is currently the therapy of choice for these patients. However, the lack of donors has forced the physician to evolve another kind of therapy such as ventricular assist device (VAD) as a bridge to transplant to compensate the lack of organs. Ventricular assist devices are today a successful therapy for the treatment of heart failure; the evolution of these devices and their progressive miniaturization have allowed an evolution of their implantation technique. To date, therefore, in addition to the traditional implant through sternotomy, there are more mini-invasive implant techniques. The purpose of the treaty is to describe these techniques, the implantation sites, and the benefits they can bring to patients.
Part of the book: Cardiac Surgery Procedures